D. Capella et al., EUROPEAN NETWORK FOR THE CASE-POPULATION SURVEILLANCE OF RARE DISEASES (EURONET) - A PROSPECTIVE FEASIBILITY STUDY, European Journal of Clinical Pharmacology, 53(5), 1998, pp. 299-302
Objective: Euronet, a case-population surveillance scheme, aims to est
imate the risk of certain rare conditions which are commonly iatrogeni
c, by comparing drug use amongst non-selective cases with overall drug
use in the general population. Methods: The method is based on three
provisos: (1) all incident cases (irrespective of suspected aetiology)
should be ascertained and studied; (2) a full drug history should be
obtained from cases by direct interview; and (3) drug-use data for the
products of interest should be available for this population from whi
ch cases are chosen. The feasibility of this problem-oriented approach
for the identification of new signals of adverse drug reactions and f
or risk estimation will be tested in relation to agranulocytosis, Stev
ens-Johnson syndrome and toxic epidermal necrolysis in four defined ar
eas in Europe, totalling 19 x 10(6) inhabitants, with these latest two
outcomes being studied in only three regions. The design, methods and
main limitations of this case-population surveillance approach are de
scribed.